Abstract
Background
The purpose of this paper is to provide technology trends and information regarding market and prospects in stents used for human blood vessels in Korea and the world.
A stent is a medical device in the form of a cylindrical metal net used to normalize flow when blood or other bodily fluids such as biliary fluids are obstructed in blood vessels, gastrointestinal tracts, etc. by inserting the stent into a narrowed or clogged area. Stents are classified into vascular and non-vascular stents. The coronary artery stent is avascular stent that is used for coronary atherosclerosis.
The demand is increasing for stents to treat diseases such as those affecting the heart and blood vessels of elderly and middle-aged patients. Due to the current shift in the demographic structure caused by an aging society, the prospect for stents seems to be very bright.
The use of a stent designed to prevent acute vascular occlusion and restenosis, which is a side effect of conventional balloon angioplasty, has rapidly become popular because it can prevent acute complications and improve clinical outcomes. Since the initial release of this stent, there have been significant developments in its design, the most notable of which has been the introduction of drug-eluting stents (DES). Bioresorbable scaffolds (BRS) have the potential to introduce a paradigm shift in interventional cardiology, a true anatomical and functional “vascular restoration” instead of an artificial stiff tube encased by a persistent metallic foreign body.
Methods
Data for this research were gathered from primary and secondary sources as well as the databases of the Korea Institute of Science Technology Information (KISTI) located in Seoul, Korea like KISTI Market Report. The sources used for primary research included the databases available from the Korea Institute of Science Technology Information, past industry research services/studies, economic and demographic data, and trade and industry journals. Secondary research was used to supplement and complement the primary research. Interviews were conducted with physicians and surgeons from the key hospitals and senior sale/marketing managers from stent product suppliers in South Korea.
Results
The global stent market is estimated at US $ 7.98 billion in 2016 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.8% over the next 5 years. As of 2016, the global market for vascular stents is estimated at $ 7.22 billion, with coronary artery stents accounting for 67.3% of the vascular stent market. Among the coronary artery stents, BRS is notably expected to grow at an annual average rate of 8.8% by 2020, but the global adoption rate of BRS remains low at present. In the Korean market, stents for blood vessels account for most of the market, and the market size of stents for blood vessels in Korea was estimated to be 145 billion won as of 2016.
Conclusions
In comparison to the sales growth rate of other medical devices, the future stent technology market is judged to be higher in growth potential.
Keywords: Vascular stent, Coronary artery stent, Drug-eluting stents (DES), Bioresorbable scaffolds (BRS), Vascular occlusion, Restenosis, Implantable medical devices, Market analysis
Background
Our society’s concerns regarding health is intensifying due to recent global trend toward aging demographics, increase of adult diseases, increase of diseases due to environmental pollution, and the emergence of new viruses. In recent years, there has been a strong emphasis on the importance of prevention and treatment through diagnosis. As the paradigm shifts to wellness, it is expected that the demand for advanced fusion diagnosis and medical devices for treatment will increase [1].
As the population ages, the area of heart disease is one of the therapeutic areas where prevention and treatment are important. Globally, heart disease has been a leading cause of deaths of people aged 60 or older and the number of people with heart disease is increasing. Therefore, the demand for medical devices for treating heart disease is expected to increase. As of 2012, WHO estimates that 37% of deaths from non-communicable diseases are attributable to heart disease and that cardiac mortality rates will increase from 17.5 million in 2012 to 22.2 million in 2030. According to the World Health Organization (WHO), it was estimated that there were about 347 million diabetics in 2014 and the risk of heart disease resulting in death reaches 42% as the blood glucose levels rise [2].
As individuals age, the blood vessels that supply oxygen and nutrients to vital organs such as the brain or heart become clogged up. The most common heart disease is myocardial infarction, which is a clogging of the heart arteries, and angina, which narrows the heart arteries. All of them are emergency medical illnesses associated with sudden death. Symptoms should be treated within 6 to 12 h after the onset of symptoms. In this case, the most commonly used procedure is coronary intervention on arteries which lead to the legs. It is a procedure to insert a cardiovascular stenosis into a blocked part using a metal wire net stent or a balloon [2]. The demand is increasing for stents to treat diseases such as those affecting the heart and blood vessels of elderly and middle-aged people. Due to current shift in the demographic structure caused by the aging of society, the prospect for stents seems to be very bright. The vascular stent market accounts for approximately 98.7% ($ 7.65 billion) of the total market (vascular and the non-vascular), and the increase of vascular disease is expected to generate continuous demand in the stent market [1].
Among vascular stents, coronary artery stents revolutionized the practice of interventional cardiology since they were first introduced in the mid-1980s [3]. The use of a stent designed to prevent acute vascular occlusion and prevent restenosis, which is a side effect of conventional balloon angioplasty, has rapidly become popular because it can prevent acute complications and improve clinical outcomes [4]. Since the initial release of these stents, there have been significant developments in their design, the most notable of which has been the introduction of drug-eluting stents (DES) [3]. Despite all the benefits of DES, concerns have been raised over their long-term safety, with reference to stent thrombosis. Newer stents have been developed in an effort to address these concerns, and examples include the following: metallic DES with durable polymers, DES with biodegradable polymers, non-polymeric DES, stents with new types of coatings, and completely biodegradable stents. Many of these stents are currently undergoing pre-clinical and clinical trials, and early results appear promising [5, 6]. First-in-man studies on small and highly selective cohorts, using multimodality intracoronary imaging, have confirmed the timing of the reabsorption process and suggested that the safety and efficacy are strong [7, 8]. Bioresorbable scaffolds (BRS) have the potential to introduce a paradigm shift in interventional cardiology, a true anatomical and functional “vascular restoration” instead of the use of artificial stiff tubes encased by a persistent metallic foreign body. Early clinical studies using the first commercially available drug-eluting bioresorbable vascular scaffold (BVS) reported very promising safety and efficacy outcomes, comparable to best-in-class second generation drug-eluting metal stents [9].
Methods
Data for this research were gathered from primary and secondary sources as well as the databases of the Korea Institute of Science Technology Information (KISTI) located in Seoul, Korea. The key areas of the research process are described below.
Primary research
The sources used for primary research included the databases available from the Korea Institute of Science Technology Information, past industry research services/studies, economic and demographic data, and trade and industry journals. This research was conducted to map and analyse market and technology trends.
Secondary research
Secondary research was used to supplement and complement the primary research. Interviews were conducted with physicians and surgeons from the key hospitals and senior sale/marketing managers from stent product suppliers in South Korea.
Results and discussion
Concept and characteristics of stents for human blood vessels
The vascular stent is used for cardiovascular stenosis. Vascular stents are classified in specifically as coronary artery stents, peripheral stents, and neurovascular stents. Peripheral stents are used for vascular diseases other than the disease of coronary arteries. Peripheral stents include carotid artery stents, iliac artery stents, femoral artery stents, and renal artery stents [1, 2, 10] (Fig. 1).
Fig. 1.
Coronary artery stents are divided into four groups depending on the material, drug release and bioabsorbability of the product: bare metal stents (BMS), DES, covered stents, and bioresorbable stents (BRS; non-drug eluting and drug eluting BRS) [11]. Furthermore, the stents are classified into BMS (1st and 2nd generation), DES (3rd generation), and BRS (4th generation), depending on their materials and characteristics [2].
A BMS is a stent made of a metal such as stainless steel and cobalt chromium (CoCr) in the form of a slotted tube or a coil. This type of stent is used to achieve high strength and excellent stretchability. The metals that compose metal stents have poor biocompatibility with the human body and cause blood clots to be easily formed. Due to these problems, many side effects such as acute vascular occlusion and chronic complications such as restenosis are caused by endarterectomy and thrombus formation after the procedure. The use of DES has been attracting attention as a means to minimize the above side effects: DES are coated with a drug-containing polymer over the surface of metal stents [10]. The structure of the DES is usually composed of a conventional bare or coated metal stent as a platform, a polymer that controls drug release by coating the drug, and a drug that is mixed with the polymer [12]. DES is different from the human tissue, and so there is a possibility that rejection will occur when the stent is inserted into the human body [10].
The drug release stent is controlled in terms of the rate at which the drug is released, depending on the type or molecular weight of the polymer and the property of the drug incorporated therein. Materials coated on the surface of the stent should have blood compatibility, tissue compatibility, non-toxicity, and stability. Biodegradable synthetic polymers such as poly(lactic-co-glycolic acid) (PLGA), poly(L-lactic acid) (PLLA) and poly(ε-caprolactone) are mainly used, since these materials satisfy such biocompatibility. Typical DES are made by coating a biodegradable polymer on a metal platform. There is a side effect, however, if a rejection reaction occurs due to the difference from the human tissue, because phosphorylcholine groups are not detectable in the coating agent used at this time [10].
Some of the current limitations of DES include the risk of the presence of metal in the body for a lifetime, the difficulty of re-operation or surgery (which can be difficult to re-perform due to the remaining metal during multiple stenting), long-term stability problems (stent thrombosis occurs due to the residual stent after several years.) and long-term use of antiplatelet agents (increased risk of bleeding) [2].
Today, drug-eluting metal stents are considered the gold standard for the interventional treatment of coronary artery disease. While they do inhibit neointimal hyperplasia, drug-eluting metal stents have many limitations such as the risk of late and very late stent thrombosis, restriction of vascular vasomotion and chronic local inflammatory reaction due to the permanent implantation of a “metallic cage,” recognized as a foreign body. BRS are a new solution, developed to overcome the limitation of the “metallic cage.” This structure provides short-term scaffolding of the vessel and then disappears, leaving nothing behind [13].
An example of a recently introduced BRS is one made of PLLA, which is the material of the suture thread. This allowed the stent to be fully absorbed into the body 1–2 years after the operation, the intrinsic function of the coronary artery vessel was restored, and the diameter of the vessel increased over time. As the result, reoperation or surgery will be easier when restenosis occurs, long-term stability is increased by reducing the risk of stent thrombosis, and the risk of bleeding is reduced due to the shortening of the duration of antiplatelet therapy [2].
Characteristics of stents used for human blood vessels
Stents comprise a growing industry, and along with the strong prospects for implantable medical devices overall, the stent market is recognized as an especially promising industry due to the full-fledged demographic shift toward the aging of society and the development of information and communication technologies (ICT). There are positive factors such as the expansion in governmental investment and the increase in market demand. Meanwhile, there are also negative factors such as the high market share of the developed countries and the lack of institutional support, which still play a significant role in keeping the Korean market very small, and the competition with global companies remains difficult. Therefore, efforts should be made to nurture related industries while improving the market environment [1].
The medical device industry, which includes BRS, is an industry in which safety and efficacy are of the highest importance, and is subject to intensive management by regulatory authorities. In addition, it is difficult to obtain licensing within the system to enter the market, and the success or failure of the business is greatly influenced by medical policies and regulations. On the other hand, it is a high-value-added field of the health industry that is growing in importance day by day, in which advanced technology is fused [10].
The stent market is expected to shift toward a concentration on the biodegradable stent market, which is currently the third generation of DES and compensates for the shortcomings of thrombosis. In the developed countries as well as in Korea, population aging is accelerating, and stenting due to cardiovascular diseases is continuously increasing, so the market stability and growth potential of the stent is high [10].
Technology trends in stents used for human blood vessels
Recent developments in stent materials and drug coatings, such as applying CoCr alloys to the stents, have increased the flexibility of the stents. To prevent stent restenosis, stents coated with a drug such as an immunosuppressive agent have been developed and are now being used widely, including 20,000 cases per year in Korea alone. Recently, stents that can be completely absorbed in the blood vessels have emerged, and these are expected to revolutionize the paradigm of stenting in the future [2].
Over the past 30 years, a number of coronary artery stents have been developed, with new variations on the material and design of the stent, the type of antiproliferative drug, and the polymer coating the drug, and thus the scope of options when choosing a stent for coronary intervention has been expanded. Recently, researchers have actively conducted clinical studies of biocompatible scaffolds. Several BRS have been proposed and have now reached clinical testing, but to date, the only one for which we have only a considerable amount of clinical data available is the Absorb (Abbott Vascular, Santa Clara, CA, USA) BVS [14]. The recent developments in stent technology are mainly driven by the development of DES. Drug-releasing stent technology has three core elements: material, structure, and drugs [1]. During the last 3 years, there have been active research and development of stents for artificial heart valves, stent-grafts, and stent supports (coatings, materials and so on.) [2].
The following table shows the status of major global applications related to the stent [15] (Table 1).
Table 1.
Status of major global applications related to stents [15]
| Applicant | US applications (number) |
Japan applications (number) |
Europe applications (number) |
Total (number) |
Technological focus |
|---|---|---|---|---|---|
| Abbott Cardiovascular Systems | 232 | 11 | 22 | 265 | Stent, biocompatible polyacrylate composition |
| Cook Medical Technologies | 77 | 22 | 32 | 111 | Stent graft, prosthesis |
| Boston Scientific Scimed | 77 | 22 | 32 | 111 | Drug release stent, shape memory polymer stent |
| Smith & Nephew | 38 | 8 | 0 | 47 | Bioabsorbable polymer, composition for tissue regeneration |
| Advanced Cardiovascular Systems | 48 | 0 | 0 | 48 | Drug Delivery Device Coating |
Various types of stents are being developed, mainly in the United States, Germany, India, and Japan, with variations in material development, product structure, and applied drugs. Most notably, many biodegradable stents are being developed [1].
DES is a stent with reduced in-stent restenosis (IRS) compared to BMS. DES has an average restenosis rate of less than 15% and reoperation rate of less than 6%. However, there is a high incidence of stent thrombosis compared to BMS [16]. The development of drug-eluting stent materials has been underway, to make the metal or biodegradable material harmless to the human body. Materials with biodegradability and biocompatibility have been actively developed, such as the PLLA polymer, Tyrosine- derived polycarbonate, magnesium alloy, and salicylic acid. To enhance the mechanical performance characteristics required of the stent, the main cell is divided into the connection cell and the main cell shape is divided into the diamond and wave pattern, and the open and closed structure are developed according to the width of the main cell and the connection cell. Drug-releasing stents have been developed using Sirolimus, Everolimus, and Biolimus, which are immunosuppressants, and Paclitaxel, which inhibits cell proliferation as an anticancer drug. Techniques related to this method of drug injection have been developed for the drug stent. The stent is coated with a drug-releasing stent, a biodegradable material, and a drug. The stent is naturally decomposed and absorbed after a certain period of time [1]. DES, which is a concept of local drug delivery, has been developed by coating the drug on a conventional stent and gradually releasing the drug. The localization of the drug has led to the emergence of DES as the main stent and various coating techniques are being developed to maximize the local drug effects [12].
DES are classified as first- and second-generation, depending on the drug used. The first-generation DES include Taxus (Paclitaxel-eluting stent) and Cypher (Sirolimus-eluting stent). The second-generation drug-eluting stent includes Xience prime (Everolimus-eluting stent), Resolute integrity (Zotarolimus-eluting stent), and Promus premier (Everolimus-eluting stent). It has been reported that DES have more very late stent thrombosis symptoms than BMS [17].
BRS is made of a material different from the metal used in conventional stents to maintain the inherent characteristics of the vessel and to reduce the risk of late thrombosis by preventing acute occlusion due to intimal injury and exfoliation using scaffold, prevent negative remodelling by maintaining blood vessel inner diameter for a certain period of 3–6 months, and prevent intimal hyperplasia by releasing an antiproliferative drug that prevents restenosis [4].
Therefore, BRS represent a new horizon in interventional cardiology for the treatment of coronary artery disease. The technology was introduced to overcome problems involved in the use of current metallic DES such as late IRS and the permanent caging of the vessel. The concept of BRS is to provide temporary support to the vessel during healing before being degraded and resorbed by the body, promoting restoration of the vessel vasomotion [18].
The following table describes developed metallic DES with durable polymers. Polymers such as poly(ethylene-co-vinyl acetate)(PEVA), poly(n-butyl methacrylate)(PBMA), Styrene-isobutylene-b-styrene (SIBS), Phosphorylcholine, and poly(vinlylidene fluoride-co-hexafluoropropylene) P(VDF-HFP) are used in the coating of metallic DES with durable polymers. Products applying metallic DES with durable polymers include Endeavor Resolute (Medtronic), Elixir DESyne (Elixir medical), TAXUS Element (Boston scientific), and Promus Element (Boston scientific) [17] (Table 2).
Table 2.
Developed metallic DES with durable polymers for coronary arteries [17]
| Stent | Manufacturer | Drug (Dose: μg/mm2) | Polymer | Polymer Thickness (μm) |
Stent Platform | Strut Thickness (μm) |
|---|---|---|---|---|---|---|
| Cypher | Cordls Corporation | Sirolimus (1.4) | PEVA+PBMA | 12.6 | SS | 140 |
| Cypher select | Cordls Corporation | Sirolimus | PEVA+PBMA | N/A | SS | 100 |
| Elixir Myolimus | Elixir Medical | Myolimus (40 μg) | Methacrylate | < 3 | CoCr | N/A |
| Endeavor | Medtronic, Inc. | Zotarolimus (10) | Phosphorylcholine | 5.3 | CoCr | 91 |
| Excella | Elixir Medical Corporation | Novolimus (0.85) | Methacrylate | 3 | CoCr | 81 |
| Promus | Boston Scientific Corporation | Everolimus (1) | Fluoropolymer | 7.6 | CoCr | 81 |
| Taxus Express | Boston Scientific Corporation | Paclitaxel (1) | SIBS (Translute) | 16 | SS | 132 |
| Taxus Liberte | Boston Scientific Corporation | Paclitaxel (1) | SIBS (Translute) | 16 | SS | 97 |
| Taxus Petal | Boston Scientific Corporation | Paclitaxel | SIBS (Translute) | N/A | Platinum Chromium | N/A |
| Xience V | Abbott Vascular | Everolimus (1) | Fluoropolymer | 7.6 | CoCr | 81 |
| ZoMaxx | Abbott Vascular | Zotarolimus (10) | Phosphorylcholine | 5 | SS/Tantalum | 74 |
SS Stainless steel and CoCr Cobalt chromium
The following table describes developed DES with biodegradable polymers. Biodegradable polymers used in the coating of DES include polyl(actic acid)(PLA), PLGA, and poly(vinyl pyrrolidone)(PVP) (Table 3).
Table 3.
Developed DES with biodegradable polymers for coronary arteries [17]
| Stent | Manufacturer | Drug (Dose) | Polymer | Polymer Thickness (μm) |
Stent platform | Strut Thickness (μm) |
|---|---|---|---|---|---|---|
| Axxess | Devax.Inc | Biolimus A-9 (15.6 μg/mm) | PLA | N/A | SS | 112 |
| BioMatrix | Biosensors International.ltd. | Biolimus-A9 (15.6 μg/mm) | PLA | 10 | SS | 137 |
| Cardiomind | CardioMind, Inc. | Sirolimus (5.2 μg/mm) | PLA + PGLA | N/A | Nitinol | 61 |
| Champion | Boston Scientific Corporation | Everolimus | PLA | N/A | SS | N/A |
| Corio | Cordis Corporation | Pimecrolimus | N/A | N/A | CoCr | 89 |
| CoStar | Cordis Corporation | Paclitaxel | PLGA | N/A | CoCr | 89 |
| Cura | OrbusNeich | Sirolimus (1.7 μg/mm2) | PLA + PLGA | 5–10 | SS | 100 |
| Excel | JW Medical Systems Ltd. | Sirolimus (195–376 μg) | PLA | N/A | SS | 150 |
| Infinnium | Sahajanand Medical Technologies Pvt.Ltd. | Paclitaxel | PLL + PLGA+PVP | N/A | SS | 84 |
| Nevo | Cordis Corporation | Sirolimus (166 μg) | PLGA | N/A | CoCr | 99 |
| Nobori | Terumo Medical corporation | Biolimus A-9 | PLA | N/A | SS | 120–149 |
| Stellium | DISA Vascular (Pty) Ltd. | Paclitaxel | PLGA | N/A | CoCr | N/A |
| Supralimus | Sahajanand Medical Technologies Pvt.Ltd. | Sirolimus (1.4 μg/mm2) | PLLA+PLGA+PVP | N/A | SS | 80 |
| Symbio | Cordis Corporation | Pimecrolimus + Paclitaxel | PLGA | N/A | CoCr | 89 |
| Synchronnium | Sahajanand Medical Technologies Pvt.Ltd. | Sirolimus + Heparin | N/A | 5–6 | SS | 60 |
| Xtent | Xtent. Inc. | Biolimus A-9 | PLA | N/A | CoCr | N/A |
SS Stainless steel and CoCr Cobalt chromium
The following table is an overview of the mechanical and physical properties of these biodegradable polyesters and their degradation rates [18] (Table 4).
Table 4.
Mechanical and physical properties of biodegradable polymers [20]
| Polymer | Tg (°C) |
Tm (°C) |
Modulus (GPa) | Strength (MPa) | Elongation at break (%) | Degradation (months) |
|---|---|---|---|---|---|---|
| PLA | 60 | 180–190 | 2–4 | 65 | 2–6 | 18–30 |
| PDLLA | 55 | Amorph. | 1–3.5 | 40 | 1–2 | 3–4 |
| PLLA | 60–65 | 175 | 2–4 | 60–70 | 2–6 | > 24 |
| PDLGA (50/50) | 45 | Amorph. | 1–4.3 | 45 | 1–4 | 1–2 |
| PLGA (82/12) | 50 | 135–145 | 3.3–3.5 | 65 | 2–6 | 12–18 |
| PCL | − 54 | 55–60 | 0.34–0.36 | 23 | > 4000 | 24–36 |
| PLA/PCL (70/30) | 20 | 100–125 | 0.02–0.04 | 2–4.5 | > 100 | 12–24 |
| WE43 (Mg alloy) | N.A | 540–640 | 40–50 | 220–330 | 2–20 | ~ 12 |
| SS 316 L | N.A | 1371–1399 | 193 | 668 | 40 | Biostable |
| CoCr | N.A | ~ 1454 | 210–235 | > 1000 | 40 | Biostable |
PLA Polylactic acid, PDLLA Poly-DL-lactic acid, PLLA Poly-L-lactic acid, PDLGA Poly-DL-lactide-co-glycolide, PLGA Poly-lactic-co glycolide, PCL Polycaprolactone, PLA/PCL Polylactic acid/polycaprolactone, Mg Magnesium, SS Stainless steel, and CoCr Cobalt chromium
The following table is a summary of the main current and upcoming BRS technologies. This section will review the underlying characteristics of these developments [18] (Table 5).
Table 5.
Summarized highlights of current BRS technologies [20]
| Company | Stent name | Strut backbone material | Strut thickness (μm) |
Key method | Radiopacity | Drug-eluting Property |
|---|---|---|---|---|---|---|
| Abbott | Absorb BVS | PLLA | 150 (BVS), 100 (Next gen) | Blow molding process and orientation (stretching) | 2 platinum radiopaque markers | Everolimus |
| Amaranth | Fortitude, Aptitude | PLLA | 150, 120 | Dip coating to induce linear/radial orientation | N/A | Sirolimus |
| ART | ART18Z | PDLLA | 170 (1st gen), 140–150 (2nd gen) | Annealing | N/A | None (1st gen), Sirolimus (2nd gen) |
| Arterius | ArterioSorb | PLLA | 140–100 | Die drawing to induce orientation and alignment | Radiopaque markers | Sirolimus |
| Elixir | DeSolve | PLLA | 150 (1st gen), 120 (2nd gen) | Annealing and quenching | Metallic markers | Novolimus |
| REVA medical Xenogenics | Fantom Ideal BioStent | Tyrosine PC, PAE salicylic acid | 125, 175 | Proprietary polymer | Iodine incorporated into the polymer or N/A | Sirolimus or Sirolimus + Salicylic acid |
| Envision Scientific | BIOLUTE-next | Mg alloy | 120 | Bio-corrodible metal and polymer coating | Radiopaque markers | Sirolimus |
BVS Bioresorbable vascular scaffold, PLLA Poly-L-lactic acid, PDLLA Poly-DL-lactic acid, PC Polycarbonate, PAE Poly(anhydride-ester), Mg Magnesium, and IBS Iron-based bioresorbable scaffold
In patients with diabetes, the use of DES was associated with a significant reduction of target lesion restenosis without an increase in adverse events, and when compared to the use of bare metal stents and the use of a polymer-free Zotarolimus and Probucol-eluting stents, the results demonstrated comparable long-term efficacy and safety as second-generation durable polymer Zotarolimus-eluting stents [19].
The market sizes and prospects for stents used in human blood vessels in Korea and the world
The global stent market is estimated at US $ 7.98 billion in 2016 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.8% over the next 5 years. As of 2016, the global market for vascular stents is estimated at $ 7.22 billion, with coronary artery stents accounting for 67.3% of the vascular stent market. Among the coronary artery stents, BRS is expected to reach an annual average growth rate of 8.8% by 2020, but the global adoption rate of BRS is still low. BRS technology is in its infancy and requires long-term clinical evidence of therapeutic efficacy. Because of the high cost of BRS devices, the market share of absorbable coronary artery stents in Korea is still low at 20% [11].
The Global Vascular Stent Market Forecast (2016–2020) is shown in the following table. As of 2016, the global market for coronary artery stents is estimated at $ 5371 million, the global market for BMS at $ 508 million, the global market for BRS at $ 205 million, and the market for DES at $ 4658 million. As of 2016, the global market for neurovascular stents is estimated at US $ 141 million and the global market for peripheral stents is estimated at US $ 1507 million [11] (Table 6).
Table 6.
Global market forecast for vascular stents (2016–2020) [Unit: million USD] [11]
| Classification | Subclass | 2016 | 2017 | 2018 | 2019 | 2020 | CAGR(%) |
|---|---|---|---|---|---|---|---|
| Coronary Artery Stents | Bare Metal Stents | 508 | 490 | 472 | 456 | 445 | −3.3% |
| Bioresorbable Stents | 205 | 221 | 240 | 262 | 287 | 8.8% | |
| Covered Stents | 140 | 141 | 144 | 147 | 152 | 2.1% | |
| Drug Eluting Stents | 4658 | 4757 | 4891 | 5067 | 5282 | 3.2% | |
| Sum | 5371 | 5468 | 5604 | 5785 | 6014 | 2.9% | |
| Neurovascular Stents | Neurovascular Stents | 141 | 150 | 160 | 171 | 182 | 6.7% |
| Peripheral Vascular Stents |
Fem-pop Artery Stents | 498 | 533 | 577 | 617 | 659 | 7.3% |
| Iliac Artery Stents | 833 | 889 | 963 | 1026 | 1094 | 7.1% | |
| Infrapop Artery Stents | 176 | 188 | 204 | 217 | 225 | 6.3% | |
| Total | 1507 | 1611 | 1744 | 1861 | 1979 | 7.0% |
Vascular stents account for approximately 98.7% of the total stent market. Coronary artery stents used for cardiovascular diseases account for about 76.1% of the stent market for blood vessels, and the market growth rate for neurovascular stents is 9.7%. However, the market size for neurovascular stents is relatively low at 1.2% compared with the cardiovascular stent, because the demand for related diseases has been low [2].
The market value of coronary artery stents is expected to decline slowly in the US and five EU countries (France, Germany, Italy, Spain, and UK) due to the decline in the average selling price and the decrease in the number of BMS and DES used in surgeries. On the other hand, the coronary stent market is expected to grow steadily in the Asia-Pacific (9.3%) and South America (3.1%), and most manufacturers are focused on the economic growth of countries in Asia, which is regarded as the main target market. China, which has a high proportion of elderly people in its population who account for a large number of procedures, is expected to become a major market for coronary stents. Although many stent manufacturers are devoted to the research and development of BRS, which represents a fast-growing market segment, BRS has a low adoption rate for clinical care because BRS technology requires long-term clinical evidence of therapeutic effects at an early stage. The following table presents data regarding market sizes and prediction of coronary artery stent usage by continent (2016–2023) [11] (Table 7).
Table 7.
Current sizes and forecasts of the market for coronary artery stents by continent (2016–2023) [Unit: million USD [11]
| Continent | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| Asia-Pacific | 2715 | 2926 | 3169 | 3448 | 3771 | 4143 | 4574 | 5072 | 9.3% |
| Europe | 917 | 888 | 861 | 836 | 810 | 786 | 765 | 740 | −3.0% |
| Middle East and Africa | 65 | 64 | 63 | 63 | 62 | 61 | 60 | 58 | −1.7% |
| South and Central America | 115 | 118 | 122 | 126 | 130 | 134 | 138 | 142 | 3.1% |
| North America | 1559 | 1471 | 1389 | 1312 | 1241 | 1175 | 1114 | 1057 | −5.4% |
| Global | 5371 | 5468 | 5604 | 5785 | 6014 | 6300 | 6651 | 7068 | 4.0% |
In the global market for coronary artery stents, the top three companies, Abbott, Boston Scientific and Medtronic, account for 76% of the market share. In the coronary artery stent market, which constitutes the largest portion of the stent market, Abbott Vascular Inc. leads the market with approximately 50% of market share, followed by Boston Scientific and Medtronic, Inc. These companies also have large market shares. In the peripheral stent market, companies such as Cordis Corporation, Abbott, and Boston Scientific have high market shares, and Abbott Vascular Inc. and Boston Scientific are likely to lead the market for cerebrovascular stents [1, 10].
Globally, as of October 2017, the development of the coronary artery stent pipeline was in the clinical stage, with 48 clinical cases accounting for 50% of the total pipeline. Currently, most of the coronary artery stent pipeline products are DES (46%), mainly in the clinical phase (60%). The following table shows global stent pipelines for coronary arteries under development [11] (Table 8).
Table 8.
Global stent pipelines for coronary arteries under development [11]
| Classification | Bare Metal Stents | Drug Eluting Stents | Bioresorbable Stents | Coronary Artery Stents |
|---|---|---|---|---|
| Early development | 0 | 6 | 6 | 7 |
| Pre-Clinical | 0 | 7 | 5 | 1 |
| Clinical | 9 | 25 | 11 | 3 |
| In Approval Process | 2 | 4 | 3 | 2 |
| Sum | 11 | 42 | 25 | 13 |
As competition intensifies, there has been much litigation regarding the infringement of intellectual property rights. One example, according to a patent litigation study by PWC in May 2017, was the infringement lawsuit filed by Cordis against Medtronic Vascular in 2005, in which $ 595 million of damages were awarded, and another was a patent infringement case filed by physician Bruce N. Saffran against Johnson & Johnson, in which $ 482 million of damages were awarded [20].
The following table shows the size and prospects of the Korean market for vessel stents [1] (Table 9).
Table 9.
Size and forecast of the Korean market for vessel stents (2015–2020) [Unit: million Korean won] [1]
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | CAGR (%) |
|---|---|---|---|---|---|---|
| 116,237 | 115,282 | 114,335 | 113,397 | 112,465 | 111,542 | −0.8 |
In the Korea, stents for blood vessels account for most of the market. In Korea, the market size for stents used in blood vessels was estimated to be 145 billion won as of 2016. Over 92% of the total Korean market for stents is comprised of imports. By 2016, Korea’s stent imports amounted to 122 billion won, accounting for 4.1% of the total import of medical devices (299.4 billion won) in Korea. In Korea, practice of coronary artery stent implantation has steadily increased to 58,064 cases as of 2013, with an average annual increase of 5.3%. [1, 17, 11, 21].
The Korean stent market is dominated by the top three importers, namely Medtronic Korea, Korea Abbott and Boston Scientific Korea, which account for about 70% of the total market. Meanwhile, the top-ranked domestic Korean company has a market share of about 5%. The market is thus highly dependent on foreign vendors [1]. As of 2016, there were 16 vessel stent importers in Korea, including Medtronic, Boston Scientific, Abbott Vascular, BIOTRONIK AG, Ashitaka Factory of Terumo Corporation, Angiomed GmbH & Co, and Medizintechnik KG. Korean manufacturers of blood vessel stents include Osstem Cardiotec and GENOSS [2, 11]. In addition, SUNTECH has acquired the cardiovascular stent business of KOSWIRE and Daewoong Pharma is also pursuing the cardiovascular stent business through its subsidiary CSII BIO. Therefore, competition in the market is expected to intensify [1].
The following table lists stent related companies in Korea and overseas and their respective core technologies [1] (Table 10).
Table 10.
Stent related companies in Korea and overseas and their core technologies [1]
| Company | Main Technology |
|---|---|
| Johnson & Johnson (MD&D) | Orthopedic (spine, etc.) implants, minimally invasive surgical instruments, wound sutures, contact lenses, blood glucose meters, catheters, stents, etc. |
| Medtronic, Inc. | Defibrillator, pacemaker, stent, catheter, spine regeneration, bone graft material, etc. |
| Covidien plc (MD) | Laparoscopic, surgical stapler, electrosurgical instruments, stents and orthopedic supplies |
| Boston Scientific Corporation | Access devices, balloon dilators, catheters, stents, slings |
| Abbott Vascular Inc | Vessel closure, structural heart, humanitarian use devices, peripheral intervention |
| Biotronik | Cardiac rhythm management, peripheral vascular intervention |
| REVA | Medical unique bioresorbable polymers |
| Zorion Medical | ZMED devices (biodegradable stent) |
| S3V Vascular Technologies | Cardio vascular, critical care |
| Japan Stent Technology | Biodegradable stents |
| OrbusNeich | Dual therapy stents, bio-engineered stents, bare metal stents, semi-compliant balloons, non-compliant balloons, specialty balloons |
| Taewoong Medical | Non-vessel stents (gastroenterology, urology, pulmonary, general surgery, cardiology) |
| MITECH CORPORATION | Stents, GI accessories |
| Sewoon Medical | Non-vessel stents |
Conclusions
There can be variances in commercial prospects within the industry depending on the market and scope of stent products, but most global market analysis reports forecast the stent market to grow at a somewhat rapid rate. Fairly rapid growth is anticipated especially in the BRS market. In comparison to the sales growth rate for medical devices in general, the stent technology market is judged to have a higher growth potential.
It is expected that social costs will increase as the population ages rapidly. Therefore, it is necessary to nurture the medical device industry to better treat the diseases of elderly patients and maintain a robust medical device industry. However, physicians who deal with implantable medical devices have a strong social awareness of the preference for foreign products. There are factors that make it challenging to enter the market through new technology development, such as aspects of governmental policy and institutions, safety and efficacy evaluation through non-clinical animal testing, clinical trial approval procedures, and the difficulty of clinical trials.
In the global market for coronary artery stents, the top three companies, Abbott, Boston Scientific, and Medtronic, have a 76% share and enjoy a monopoly position in the market, making the entry of new companies difficult. Korea also has a chronic trade deficit in the stent field. Although many stent manufacturers are devoted to the research and development of BRS, the fast-growing market segment, the rates of the adoption of BRS in clinical practice are low, as BRS technology requires long-term clinical evidence of therapeutic effects in its early stages.
Vascular stents account for approximately 98.7% of the total stent market. Coronary artery stents used for cardiovascular diseases account for about 76.1% of the stent market for blood vessels, and the market growth rate for neurovascular stents is 9.7%. However, the market size for neurovascular stents was relatively low at 1.2% compared with cardiovascular stents, because the demand arising from related diseases was low.
The coronary artery stent market value is expected to decline slowly in the US and 5 EU countries (France, Germany, Italy, Spain, and UK) due to the decrease in the average selling price and the number of BMS and DES used in surgeries. On the other hand, the coronary stent market is expected to grow steadily in the Asia-Pacific (9.3%) and South America (3.1%), and most manufacturers are focused on the economic growth of countries in Asia, which is regarded as the main target market. China has a high proportion of elderly in its population who account for the demand for procedures and is expected to become a major market for coronary stents.
The prospect for stents seems to be very bright due to current shift toward an aging demographic structure.
Acknowledgements
Not applicable
Funding
This study is supported by Korea Institute of Science and Technology Information (KISTI).
Availability of data and materials
All data generated and analysed in this study are included in this article.
Authors’ contributions
JHL primarily conducted research. EJJ and EDK participated in the design of the research and helped to draft the manuscript. HSY helped to perform the statistical analysis and database research. JWL conceived of the research and participated in its design and coordination as the corresponding author. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Jeong Hee Lee, Email: smartbio@naver.com.
Eung Do Kim, Email: edkim@chungbuk.ac.kr.
Eun Jung Jun, Email: jun@auriosmedical.com.
Hyoung Sun Yoo, Email: hsyoo@kisti.re.kr.
Joon Woo Lee, Email: jwlee@kisti.re.kr.
References
- 1.Human implantable medical device - Stent . KISTI market report. 2016. [Google Scholar]
- 2.Stent . KISTI business opportunity supporting system. 2016. [Google Scholar]
- 3.Garg S, Serruys PW. Coronary stents-current status. J Am Coll Cardiol. 2010;56(10):S1–S42. doi: 10.1016/j.jacc.2010.06.007. [DOI] [PubMed] [Google Scholar]
- 4.Shin E-S.Current status of coronary stent. Korean J Med. 2015;89:282-90.
- 5.Garg S, Serruys PW. Coronary stents-looking forward. J Am Coll Cardiol. 2010;56(10):S43–S78. doi: 10.1016/j.jacc.2010.06.008. [DOI] [PubMed] [Google Scholar]
- 6.Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616):899–907. doi: 10.1016/S0140-6736(08)60415-8. [DOI] [PubMed] [Google Scholar]
- 7.Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897–910. doi: 10.1016/S0140-6736(09)60325-1. [DOI] [PubMed] [Google Scholar]
- 8.Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade. Eur Heart J. 2012;33(1):16–25b. doi: 10.1093/eurheartj/ehr384. [DOI] [PubMed] [Google Scholar]
- 9.Caiazzo G, Kilic ID, Fabris E, Serdoz R, Mattesini A, Foin N, De Rosa S, Indolfi C, Di Mario C. Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience? Int J Cardiol. 2015;201:129–136. doi: 10.1016/j.ijcard.2015.07.101. [DOI] [PubMed] [Google Scholar]
- 10.Lee JH, Yoo HS, Seo J. Drug-releasing biodegradable stent, Technical Valuation Report, KISTI. October 2016. p. 1-102.
- 11.Stent, KhIDI Brief . Korea Health Industry Development Institute (KhIDI) 2017. [Google Scholar]
- 12.S-J Kim, J-G Park, JH Kim, IK Kwon, An Overview of Researches Trend in Drug-Eluting Stents Development. Biomater Res. 2010;14(1):37–49.
- 13.Brie D, et al. Bioresorbable scaffold — a magic bullet for the treatment of coronary artery disease? Int J Cardiol. 2016;215:47–59. doi: 10.1016/j.ijcard.2016.04.027. [DOI] [PubMed] [Google Scholar]
- 14.Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123(7):779–797. doi: 10.1161/CIRCULATIONAHA.110.971606. [DOI] [PubMed] [Google Scholar]
- 15.WIPS. Bio, Technology Roadmap for SME 2017–2019, Korea Minstry of SME. 2016. p. 1-334.
- 16.Long-term Technology Roadmap Planning to Overcome Cardio-Cerebrovascular Disease . Korea centers for disease control and prevention. 2012. [Google Scholar]
- 17.Choi C, Nah J-W, Park J-K. Development trends of the stent for coronary artery. KIC News. 2015;18:10-24.
- 18.Ang HY, et al. Bioresorbable stents: current and upcoming bioresorbable technologies. Int J Cardiol. 2017;228:931–939. doi: 10.1016/j.ijcard.2016.11.258. [DOI] [PubMed] [Google Scholar]
- 19.Wiemer, et al. Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. Cardiovasc Diabetol. 2017;16:23. doi: 10.1186/s12933-017-0500-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.ICT Patent Disputes and Patent Trends Related to the Fourth Industrial Revolution, Weekly Technology Trends . Institute for information & communications technology promotion. 2017. [Google Scholar]
- 21.2017 Healthcare Outlook . Hanyang securities research center. 2016. [Google Scholar]
- 22.Stent Technology Trend . Korea health industry development institute. 2014. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated and analysed in this study are included in this article.